Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4100 participants.

Also called NCT05881382

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,100 participants (planned count) (from the registry)
Sponsor
Recardio, Inc. (from the registry)
Registry
  • NCT NCT05881382
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05881382. Randomized; quadruple masking; primary purpose treatment. Start 2023-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
Acronym
HEAL-MI
Condition
ST Elevation Myocardial Infarction
Intervention (Drug)
Dutogliptin + Filgrastim
Intervention (Drug)
Placebo
Lead sponsor
Recardio, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05881382
Content hash
d523572d151d34bea4b58e9657ac2cc42749e20d74560663f3559084c9211f0b